Mikhail Akimov

Mikhail Akimov

UNVERIFIED PROFILE

Are you Mikhail Akimov?   Register this Author

Register author
Mikhail Akimov

Mikhail Akimov

Publications by authors named "Mikhail Akimov"

Are you Mikhail Akimov?   Register this Author

13Publications

598Reads

39Profile Views

Phase Ib/II Study of Capmatinib (INC280) Plus Gefitinib After Failure of Epidermal Growth Factor Receptor (EGFR) Inhibitor Therapy in Patients With EGFR-Mutated, MET Factor-Dysregulated Non-Small-Cell Lung Cancer.

J Clin Oncol 2018 11 29;36(31):3101-3109. Epub 2018 Aug 29.

Yi-Long Wu, Guangdong General Hospital and Guangdong Academy of Medical Sciences; Li Zhang, Sun Yat-sen University Cancer Center, Guangdong; Xiaoqing Liu, Affiliated Hospital of the Chinese Academy of Military Medical Sciences, Beijing; Sylvia Zhao and Bin Peng, Novartis Institutes for Biomedical Research, Shanghai, People's Republic of China; Dong-Wan Kim, Seoul National University Hospital; Dae Ho Lee, University of Ulsan College of Medicine; Myung-Ju Ahn, Samsung Medical Center, Seoul, Republic of Korea; James Chih-Hsin Yang, National Taiwan University Hospital, Taipei; Wu-Chou Su, National Cheng Kung University Hospital, Tainan, Taiwan; Johan F. Vansteenkiste, University Hospital KU Leuven, Leuven, Belgium; Enriqueta Felip, Vall d'Hebron University Hospital, Barcelona, Spain; Vincent Chia and Philippe Pultar, Novartis Pharmaceuticals, East Hanover, NJ; Sabine Glaser and Mikhail Akimov, Novartis Pharma AG, Basel, Switzerland; and Daniel S.W. Tan, National Cancer Centre Singapore, Singapore.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2018.77.7326DOI Listing
November 2018

Ocular toxicity of AUY922 in pigmented and albino rats.

Toxicol Appl Pharmacol 2016 10 28;309:55-62. Epub 2016 Aug 28.

Preclinical Safety, Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.taap.2016.08.025DOI Listing
October 2016

Cytotoxicity of Endogenous Lipids N-acyl Dopamines and their Possible Metabolic Derivatives for Human Cancer Cell Lines of Different Histological Origin.

Anticancer Res 2015 May;35(5):2657-61

Shemyakin-Ovchinnikov Institute of Bioorganic Chemistry, Russian Academy of Sciences, Moscow, Russia.

View Article

Download full-text PDF

Source
May 2015

Phase I dose-escalation study of the HSP90 inhibitor AUY922 in Japanese patients with advanced solid tumors.

Cancer Chemother Pharmacol 2014 Sep 25;74(3):629-36. Epub 2014 Jul 25.

National Cancer Center Hospital East, 6-5-1 Kashiwanoha, Kashiwa, Chiba, 277-8577, Japan,

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00280-014-2521-xDOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4143601PMC
September 2014

Inhibition of HSP90 with AUY922 induces synergy in HER2-amplified trastuzumab-resistant breast and gastric cancer.

Mol Cancer Ther 2013 Apr 8;12(4):509-19. Epub 2013 Feb 8.

University of California Geffen School of Medicine, Department of Medicine, Division of Hematology/Oncology, Santa Monica, CA 90404, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1535-7163.MCT-12-0507DOI Listing
April 2013